MNKD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

100.96M

+31.5%

0.019

-53.13%

107.80M

+37.58%

0.019

-37.5%

112.15M

+46.55%

-0.005

-112.5%

Estimates Revision

The market is revising Upward the revenue expectations for MannKind Corporation (MNKD) for FY2025, with the revenue forecasts being adjusted by 6.81% over the past three months. During the same period, the stock price has changed by 13.81%.

Revenue Estimates for FY2025

Revise Upward

+6.81%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.75%

In Past 3 Month

Stock Price

Go Up

+13.81%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.50 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.50

Averages

9.25

High

11.00

Current: 0.000

Low

7.50

Averages

9.25

High

11.00

H.C. Wainwright

Buy

maintain

$11

2026-01-08

New

Reason

H.C. Wainwright

Price Target

$11

2026-01-08

New

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on MannKind with an $11 price target after the company provided a 2026 business update. The firm is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026." The FDA decision on Afrezz's label update concerning dose conversion for mealtime insulin switching is on January 23, and a separate application for pediatric use in type 1/2 diabetes has a May 29 action date, the analyst tells investors in a research note.

Truist

initiated

2025-11-24

Reason

Truist

Price Target

2025-11-24

initiated

Reason

Truist initiated coverage of MannKind with a Buy rating and $9 price target. MannKind continues to execute with their technology, with both Afrezza and Tyvaso DPI, and the recent acquisition of scPharmaceuticals adds another topline driver, Furoscix, for fluid overload, the analyst tells investors in a research note. MannKind's orphan lung pipeline continues to advance for longer-term diversification and growth for the company, Truist says.

Oppenheimer

Outperform

NULL

downgrade

$15 -> $10

2025-11-11

Reason

Oppenheimer

Price Target

$15 -> $10

2025-11-11

downgrade

Outperform

NULL

Reason

Oppenheimer lowered the firm's price target on MannKind to $10 from $15 and keeps an Outperform rating on the shares after removing MNKD-101/NTM from its pipeline valuation. The firm cites discontinuation of the Phase 3 ICoN-1 trial for nontuberculosis mycobacterial lung disease after a review by the Data Safety Monitoring Board determined that proceeding with the study would be futile as no sputum culture conversions were observed.

Oppenheimer

Outperform

maintain

$12 -> $15

2025-09-05

Reason

Oppenheimer

Price Target

$12 -> $15

2025-09-05

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on MannKind to $15 from $12 and keeps an Outperform rating on the shares. The firm is updating its model to include TYVASO DPI royalties following positive Phase 3 results from TETON-2 in IPF and FUROSCIX following the acquisition of scPharma. Oppenheimer sees TYVASO becoming a backbone therapy in IPF generating about $5.4B in sales in 2033 and subsequently enhancing MannKind's DPI royalty stream.

RBC Capital

Douglas Miehm

Outperform

maintain

$7 -> $8

2025-08-26

Reason

RBC Capital

Douglas Miehm

Price Target

$7 -> $8

2025-08-26

maintain

Outperform

Reason

RBC Capital analyst Douglas Miehm raised the firm's price target on MannKind (MNKD) to $8 from $7 and keeps an Outperform rating on the shares. The firm views the company's announced acquisition of scPharmaceuticals (SCPH) positively as it adds a high-growth commercial asset with a large total addressable market of about $13B, diversifies MannKind revenue base, and the acquisition multiple is "attractive", the analyst tells investors in a research note.

H.C. Wainwright

Brandon Folkes

Buy

maintain

2025-08-06

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-08-06

maintain

Buy

Reason

H.C. Wainwright analyst Brandon Folkes views the selloff in shares of MannKind post the Q2 report as overdone. The market "continues to miss" the drivers of MannKind's future, which include Afrezza pediatric uptake and the pipeline of MNKD-101 and MNKD-201, the analyst tells investors in a research note. The firm believes the Q2 updates on MannKind's future value drivers were largely positive. H.C. Wainwright believes the stock remains undervalued fundamentally. It keeps a Buy rating on MannKind with a $9 price target.

Valuation Metrics

The current forward P/E ratio for MannKind Corp (MNKD.O) is 83.46, compared to its 5-year average forward P/E of 18.19. For a more detailed relative valuation and DCF analysis to assess MannKind Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

18.19

Current PE

83.46

Overvalued PE

81.35

Undervalued PE

-44.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.55

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

19.53

Undervalued EV/EBITDA

-38.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.21

Current PS

3.80

Overvalued PS

10.77

Undervalued PS

3.65

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1407.97% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 337.78% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1407.97% over the last month.

Sold

Bought

MNKD News & Events

Events Timeline

No data

News

7.5

01-08Globenewswire

MannKind Acquires scPharmaceuticals, Expects Over $100M Net Revenue in 2026

5.0

2025-12-25Fool

MannKind CEO Castagna Sells 65,804 Shares for Approximately $395,482

5.0

2025-12-25NASDAQ.COM

MannKind CEO Castagna Sells 65,804 Shares for ~$395,482

People Also Watch

Frequently Asked Questions

What is MannKind Corp (MNKD) stock price today?

The current price of MNKD is 5.85 USD — it has decreased -2.66 % in the last trading day.

What is MannKind Corp (MNKD)'s business?

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What is the price predicton of MNKD Stock?

What is MannKind Corp (MNKD)'s revenue for the last quarter?

MannKind Corp revenue for the last quarter amounts to 82.13M USD, increased 17.20 % YoY.

What is MannKind Corp (MNKD)'s earnings per share (EPS) for the last quarter?

MannKind Corp. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for MannKind Corp (MNKD)'s fundamentals?

How many employees does MannKind Corp (MNKD). have?

MannKind Corp (MNKD) has 407 emplpoyees as of January 10 2026.

What is MannKind Corp (MNKD) market cap?

Today MNKD has the market capitalization of 1.80B USD.